Glaukos

Yahoo Finance • 2 days ago

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

https://www.tipranks.com/news/the-fly/apple-unveils-iphone-16e-arista-reports-q4-beat-morning-buzz Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. Discover the Best Stocks and Maximize Your P... Full story

Yahoo Finance • 4 months ago

Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety

Phase 3 Confirmatory Trial Met Pre-Specified Primary Efficacy Endpoint and Demonstrated Excellent Tolerability and a Favorable Safety Profile Through 12 Months, Supporting Anticipated New Drug Application (NDA) Submission by End of 2024 D... Full story

Yahoo Finance • 7 months ago

Should You Be Bullish on Glaukos Corporation (GKOS)?

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund declined 2.55% (Institutional Shares) in the quarter compared t... Full story

Yahoo Finance • 7 months ago

Glaukos Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Glaukos (NYSE:GKOS) Second Quarter 2024 Results Key Financial Results Revenue: US$95.7m (up 19% from 2Q 2023). Net loss: US$53.9m (loss widened by 64% from 2Q 2023). US$1.06 loss per share (further deteriorated from US$0.68 loss in 2Q 20... Full story

Yahoo Finance • last year

Insider Sell: Glaukos Corp's President & COO Joseph Gilliam Sells 1,512 Shares

On February 12, 2024, Joseph Gilliam, President & COO of Glaukos Corp, executed a sale of 1,512 shares of the company. The transaction was filed with the SEC and can be found in the official documentation. Glaukos Corp is a medical techno... Full story

Yahoo Finance • last year

Glaukos Announces Participation in Stifel Healthcare Conference

ALISO VIEJO, Calif., November 07, 2023--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal... Full story

Yahoo Finance • 2 years ago

These 2 Soaring Stocks Finished the Week Strong

The upward momentum in the stock market this week ran out of steam on Friday afternoon, as the Nasdaq Composite (NASDAQINDEX: ^IXIC) and S&P 500 (SNPINDEX: ^GSPC) gave up early gains to close slightly lower. Aehr Test Systems (NASDAQ: AEHR... Full story

Yahoo Finance • 2 years ago

Glaukos Submits New Drug Application to U.S. FDA for iDose TR

ALISO VIEJO, Calif., February 27, 2023--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal... Full story

Yahoo Finance • 2 years ago

15 Small Innovative Companies According to the Media

In this piece, we will take a look at the fifteen small innovative companies according to the media. For more small and innovative companies, head on over to 5 Small Innovative Companies According to the Media. Innovation is the bedrock o... Full story

Yahoo Finance • 2 years ago

15 Largest Ophthalmology Companies in the World

In this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompa... Full story

Yahoo Finance • 3 years ago

Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium

SAN CLEMENTE, Calif., May 20, 2022--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal dise... Full story

Yahoo Finance • 3 years ago

Glaukos Corporation Announces First Quarter 2022 Financial Results

SAN CLEMENTE, Calif., May 04, 2022--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal dise... Full story